EWTX vs ERAS
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
EWTX · Edgewise Therapeutics$39.91 ▼ 3.07%
ERAS · Erasca$13.61 ▼ 4.29%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- EWTX +70.0%
- ERAS +370.9%
Head to head
| Metric | EWTX | ERAS |
|---|---|---|
| Price | $39.91 | $13.61 |
| Change today | ▼ 3.07% | ▼ 4.29% |
| Market cap | $4.37B | $4.78B |
| Return, 3 months | -10.8% | -22.7% |
| Return, year to date | +60.8% | +265.9% |
| Return, 1 year | +76.0% | +366.1% |
| P/E (TTM) | 4.8 | – |
| P/B | 2.7 | 5.2 |
| P/E percentile vs own 5y | 100th | 12th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | – | – |
| Net profit growth (YoY) | +2,967.6% | -67.7% |
| Gross margin | – | – |
| Operating margin | – | – |
| Net margin | – | – |
| Return on equity | 92.1% | -48.7% |
| Analyst target vs. price | +47.6% | +81.3% |
| Analyst buy share | 100% | 67% |
| RSI (14) | 44 | 43 |
| 30-day volatility | 65.9% | 81.2% |
| Max drawdown, 1 year | -25.0% | -59.5% |
| Trend read | Leaning bearish | Strong downtrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- ERAS is the largest of the group by market value.
- ERAS has returned the most over the past year.
- EWTX has been the calmest stock over the last 30 days.